Tags

Type your tag names separated by a space and hit enter

Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67.
Int Orthop. 2016 Nov; 40(11):2393-2399.IO

Abstract

PURPOSE

To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy.

METHODS

The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and β-catenin.

RESULTS

Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p < 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours.

CONCLUSIONS

This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.

Authors+Show Affiliations

Institute for Orthopedic Surgery "Banjica", School of Medicine, University of Belgrade, M. Avramovica St. 28, 11000, Belgrade, Serbia.Institute for Pathology, Medical Faculty, School of Medicine, University Belgrade, Dr Subotica 1, 11000, Belgrade, Serbia.Institute for Pathology, Medical Faculty, School of Medicine, University Belgrade, Dr Subotica 1, 11000, Belgrade, Serbia.Institute for Orthopedic Surgery "Banjica", School of Medicine, University of Belgrade, M. Avramovica St. 28, 11000, Belgrade, Serbia. drvladanstevanovic@gmail.com.Institute of Nuclear Sciences "Vinča", University of Belgrade, Mike Alasa 12-14, 11000, Belgrade, Serbia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27658412

Citation

Lujic, Nenad, et al. "Recurrence of Giant Cell Tumour of Bone: Role of P53, Cyclin D1, Β-catenin and Ki67." International Orthopaedics, vol. 40, no. 11, 2016, pp. 2393-2399.
Lujic N, Sopta J, Kovacevic R, et al. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67. Int Orthop. 2016;40(11):2393-2399.
Lujic, N., Sopta, J., Kovacevic, R., Stevanovic, V., & Davidovic, R. (2016). Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67. International Orthopaedics, 40(11), 2393-2399.
Lujic N, et al. Recurrence of Giant Cell Tumour of Bone: Role of P53, Cyclin D1, Β-catenin and Ki67. Int Orthop. 2016;40(11):2393-2399. PubMed PMID: 27658412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67. AU - Lujic,Nenad, AU - Sopta,Jelena, AU - Kovacevic,Relja, AU - Stevanovic,Vladan, AU - Davidovic,Radoslav, Y1 - 2016/09/22/ PY - 2016/07/13/received PY - 2016/09/05/accepted PY - 2016/10/28/pubmed PY - 2018/1/25/medline PY - 2016/9/24/entrez KW - Cyclin D1 KW - Giant cell tumour of bone KW - Recurrence KW - p53 SP - 2393 EP - 2399 JF - International orthopaedics JO - Int Orthop VL - 40 IS - 11 N2 - PURPOSE: To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. METHODS: The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and β-catenin. RESULTS: Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p < 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. CONCLUSIONS: This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB. SN - 1432-5195 UR - https://www.unboundmedicine.com/medline/citation/27658412/Recurrence_of_giant_cell_tumour_of_bone:_role_of_p53_cyclin_D1_β_catenin_and_Ki67_ L2 - https://dx.doi.org/10.1007/s00264-016-3292-2 DB - PRIME DP - Unbound Medicine ER -